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1. Introduction 
The regulatory role of HMG-CoA reduetase 
(EC 1.1 .I .88) was first demonstrated for hepatic 
cholesterol biosynthesis from acetate in fasted [ 1 J 
and in cholesterol-fed rats [2]. Much progress has 
since been made towards an understanding of the 
control of this enzyme by a cholesterol-dependent 
feedback mechanism, mediated through low density 
lipoprotein. The use of a specific inhibitor, compactin 
[3], has furthermore led to the discovery of multi- 
valent feedback inhibition of HMG-CoA reductase 
and to insights into the coordination of isoprenoid 
biosynthesis and cell growth (reviews [4,5]). 
During studies on the mech~ism of action of 
citrate synthase (EC 4.1.3.7) we synthesized (3R,S)- 
3,4-dicarboxy3-hydroxybutyl-CoA (I), an inhibitory 
intermediate analogue of the synthase reaction [6,7]. 
To establish the specificity of (1) we have also pre- 
pared the title compound (II), a substrate analogue 
for HMG-CoA reductase. 
If (I) represents a specific inhibitor of citrate syn- 
thase, (II) should not be inhibitory; the reverse should 
be found with HMG-CoA reductase. This mode of 
inhibition provided, (II) should further not affect the 
rest of the enzymes involved in cholesterol biosyn- 
thesis. The results presented here demonstrate this 
specificity. 
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2. Material and methods 
(3~,~)-3-Hydroxy-3-methyl[3-14CJ~utaryl-~oA 
(54 mCi/mmol), (3~,~)-[S-3H]mevalolactone 
5.7 mCi/mmol), (3R,S)-[2-“4CJmevaIolactone (47mCi/ 
mmol), [ 1 -14C]acetate (44 mCi/mmol) and [ 1 -14C]- 
acetyl-CoA (5 7 mCi/mmoI) were purchased from 
New England Nuclear. Glucose&phosphate, glucose- 
6-phosphate dehydrogenase (EC 1 .I .I .49; 6 E.lkat/mg 
protein), citrate synthase and other biochemicals 
were from Boehringer Mannheim GmbH. Cholestyr- 
amine was from Serva, Heidelberg; Biorad (1 X 8; 
Cl-; 100-200 mesh) was from Biorad Laboratories 
and Unisolve 100 from Zinsser , Frankfurt. The 
inhibitor (I) was prepared as in 161; (II) was similarly 
obtained in the sequence methyl (R,S)-mevalonate + 
methyl (R,S)-3-hydroxy-3-hydroxy-3-methyl-4-car- 
boxybutylbromide + II (in preparation). 
2.1. Anirnds 
Male Sprague-Dawley rats (-180 g body wt) were 
housed in a light-controlled room on an alternate 12 h 
lint-dark schedule (dark phase 4 a.m.-4 p.m.)..The 
animals were fed ad libitum for 5 days a 2% choles- 
tyramine-containing diet (Rattendigt-Zuchtfutter; J. 
Stetter, Munich). The rats were sacrificed at 10 a.m. 
2.2. Putifkation of HMG-CoA reductase 
Purification of microsomes from excised livers 
(-100 g) and solubilisation of enzyme were per- 
formed as in 181. The reductase was purified through 
the heat step and ammonium sulfate precipitation 
(O-50% saturation) as in [X] to yield 6 mg (45 nkat) 
protein dissolved in 1 .O ml buffer A [8]. 
2.3. Assays 
Activity of HMG-CoA reductase was determined 
14.5 
Volume 128, number 1 FEBS LETTERS June 198 1 
as in [$I]. The reaction mixture which was kept at 
37°C in a total volume of 0.2 ml contained 0.1 mM 
(R,,YY)-[~-‘~C]HMG-COA (1.32 X 1 O5 cpm), 0.23-0.45 
nkat reductase (which was used to start the reaction) 
and (assay 1; in work with crude extracts) 0.1 M Tris 
buffer (pH 7.2); 20 mM EDTA; 0.1 M neutralized 
cysteine hydrochloride; 10 mM glucosed-phosphate; 
1 mM NADP and 12 nkat glucose-6-phosphate dehy- 
drogenase or (assay 2; in work with purified enzyme 
samples) 25 mM phosphate buffer (K’) (PH 7.0); 
1 mM dithiothreitol; 10 mM EDTA and 0.5 mM 
NADPH. With purified enzyme samples both assays 
yielded identical results. 
The samples after start of the reaction were 
incubated for 10 min; (R,S)-[S-3H]mevalonate 
(5 pmol; 8 X IO4 cpm) was then added and the reac- 
tion was terminated by adding 0.10 ml 2 N HzS04. 
Mevalonic acid lactone was isolated as in [9]; samples 
(5 ml each) were mixed with 15 ml Unisolve 100 and 
the radioactivity was determined in a Berthold- 
Betascint 5000/300 scintillation counter. 
2.4. Protein determination 
This was done by the biuret method; enzyme units 
are expressed in kat. 
2.5. Incorporation experiments 
Rat liver microsomes and cytosolic enzyme frac- 
tion were isolated according to [IO], modified as in 
[ 111. The reaction mixture which was kept at 37°C 
in a total volume of 0.20 ml contained 0.1 M Tris 
buffer (pH 7.2); 1 mM ATP; 10 mM glucose-6-phos- 
phate; 6 mM glutathione; 6 mM MgC12;40 PM CoASH; 
0.25 mM NAD; 0.25 mM NADP; 0.05 mg microsome 
protein; 0.5 mg cytosolic fraction protein and 22.8 nM 
[ 1-r4C]acetate (44 mCi/mmol). In some experiments 
[ 1-14C]acetate was replaced by 17.3 ,uM [ I-‘4C]acetyl- 
CoA(57 mCi/mmol), 18.5 I.IM (R,S)-[3-‘4C]HMG- 
CoA or 32.4 PM (R,S)-[2-‘4C]mevalonate (47 mCi/ 
mmol). The reaction was stopped after 10 min by 
adding 1 ml 15% ethanolic KOH containing 1 ~01 
unlabelled carrier cholesterol and the products were 
hydrolyzed for 1 hat 75°C. Extraction was performed 
with petroleum ether (1 X S,2 X 2 ml) and the com- 
bined extracts were washed with 1 ml water; 10 ml 
Unisolve 100 was added and the radioactivity was 
determined as in section 2.3. The incorporations of 
the substrates were proportional to time for at least 
30 min. 
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1;ig.l. (A) Inhibition of HMG-CoA reductase by (II) I’S HMG- 
CoA. Assays were performed with purified enzyme as in sec- 
tion 2 but with HMGCoA varied as indicated. The concentra- 
tion (PM) of (II) was: zero (0); 9.25 (*); 14.9 (0); 22.4 (A); 
27.8 (m); 37.3 (v); and 46.3 (0). (B) Replot of app Km vs 
[inhibitor]. 
3. Results 
3.1. Inhibition of HMG-CoA reductase 
The kinetics of the reductase reaction (HMG-CoA 
varied) without and in the presence of increasing con- 
centrations of (II) are presented as double reciprocal 
plots in fig.1 A and indicate competitive inhibition. 
A replot of app Km taken from fig.lA vs inhibitor 
concentration is shown in fig.lB, from which k’i = 
7 nM (R,S) was determined; Km for HMG-CoA was 
8 ,uM (R,S). Tile inhibition of the reductase by (II) on 
variation of NADPH was non-competitive (fig.2A) 
- 
I/NAQPH I mK'1 
Fig.2. (A) Inhibitionof HMGCoA reductase by (II) vs NADPH. 
Assays were performed with purified enzyme as in section 2 
but with NADPH varied as indicated. The concentration (PM) 
of II was: zero (o), 38 (*), 76 (A) and 114 (9). (B) Rcplot of 
l/‘app vs (inhibitor]. 
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Inhibitory effects of I, II and CoASH on HMGCoA reductase 
-- 
Inhibitor (JIM) Mevalonate % of 
. (nmol)a control 
I II CoASH 
None None None 1 .68 100 
9.1 - _ 1.54 91 
- 9.3 - 1.02 61 
_ _ 9.3 1.55 92 
27.4 - _ 1.44 86 
- 27.8 _ 0.70 42 
- - 27.8 1 so 89 
-______ 
a nmol mevalonate X (10 min X mg protein)-’ formed under 
assay conditions in section 2; 35 pg protein (0.26 nkat) was 
applied 
Table 1 Table 2 
Effects of II on the incorporation of “C-labelled precursors 
of cholesterol biosynthesis into non-saponifiable lipids 
-~ 
Substrate Inhibitor incorpora- % of 
II (PM) tiona control 
(cpm) 
-. 
[ 1-i4C]Acetate None 5200 
30 3660 70 
90 2710 52 
[ l-‘4C]AcetylCoA None 9440 
30 7240 77 
90 4180 43 
(R,S)-[3-i4C]HMG-CoA None 13 060 
30 8940 68 
90 5500 42 
and yielded Xi (II) = 100 PM (fig.2B) and Km 
(NADPH) = 23 FM. 
3.2. Specijicity of inhibitors (I) and (II) 
(R,S’)-[ 2-‘4C]Mevalonate None 11500 
30 10 520 92 
90 10 600 92 
-.. 
The activity of citrate synthase is strongly depressed 
in the presence of I [7] and so is that of ATP citrate 
lyase (EC 4.1.3.8) (U. Lill, unpublished). Substitution 
of (I) for (II)in the assays of the two enzymes yielded 
an inhibition as low as that effected by CoASH. Citrate 
synthase: Ki (COASH) - Ki (II) - 250 PM; ATP 
citrate lyase: 25 PM CoASH or (II) caused 10% inhi- 
bition. 
a Experiments were performed as in section 2 
the citrate synthase reaction [7]_ Replacement of the 
3-carboxyl group in (1) by a methyl group yields 
(II) concomitant with the loss of inhibitory power 
vs this enzyme. Similarly, also (3R)citryLCoA is not 
inhibitory towards citrate synthase (in preparation). 
The reversed specificity of the inhibitors (I) and 
(II) for HMG-CoA reductase is shown in table 1. In 
the presence of 28 FM (II) the reductase was strongly 
inhibited, to ++60%, whereas 28 PM (I) or CoASH 
yielded only -10% inhibition. 
3.3. Inhibition of con-saponi~ab~e lipid biosynthesis 
The inhibitory effect of (II) on the incorporation 
of several different precursors of cholesterol biosyn- 
thesis into nonsaponifiable lipids is shown in table 2. 
Similar to the action of compactin 131, albeit at 
higher concentrations, (Ii) suppressed the incorpora- 
tion of acetate, acetyl-CoA and HMG-CoA but was 
without effect towards the incorporation of mevalon- 
ate into non-saponifiable lipids. 
The interlnediate analo~e (II) of the HMG-CoA 
reductase reaction specifically inhibited the reductase 
which was hardly influenced by (I). The results match 
those obtained with the corresponding acyl-CoA 
derivatives. The substrate of the reductase, (3R,S)- 
HMG-CoA, is not inhibitory towards citrate synthase 
and the substrate for the latter enzyme, (3S)-citryl- 
CoA, is not inhibitory towards the reductase. ATP 
citrate lyase is likewise neither inhibited by HMG-CoA 
nor by (II) but by (I), as expected if (3S)citryLCoA 
is formed as an intermediate on this enzyme [ 121. 
The conclusion in [7] can therefore be extended in 
that not only the affinity but also the specificity 
appears to be unaffected in substrate analogues form- 
ed by replacement of oxygen next to sulfur of acyl- 
CoA derivatives by hydrogen. 
4. Discussion 
These results demonstrate the specificity of inhib- 
itors (I) and (II) and therefore strengthen the conclu- 
sion that (I) represents an intermediate analogue of 
As judged from incorporation studies of radio- 
actively labelled precursors of cholesterol biosynthesis 
into non-saponi~abie lipids, HMG-CoA reductase was 
the target enzyme for (II), which had no effect on 
other enzymes involved in this biosynthesis. The 
affinity of (II) towards the reductase is nearly identical 
to that of HMG-CoA but -3 powers of 10 lower 
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than that of compactin [3]. Nevertheless the chemical 
and enzymological properties of (II) suggest hat it 
may basically represent a useful component in future 
attempts to repress hypercholesterinaemia. 
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